BioSpace News Archive

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced today that it will host a conference call.

Researchers will discuss how they employed HEPATOPAC® and HEPATOMUNE® cultures in their disease modeling, lead selection, and ADME evaluation programs.

Medpace Holdings, Inc. announced financial results for the third quarter ended September 30, 2021.

Simulations Plus, Inc. today reported financial results for its fourth quarter and full year 2021 fiscal year, ended August 31, 2021.

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), today announced that it will release financial results for the third quarter of 2021 after the U.S. market close on Wednesday, November 10th, 2021.

Geron Corporation announced that imetelstat, the Company’s first in class telomerase inhibitor, has been granted an Innovation Passport, which is the first prescribed entry point to the Innovative Licensing and Access Pathway launched in the United Kingdom by the Medicines and Healthcare products Regulatory Agency in January 2021, post-Brexit.

Ventyx Biosciences, Inc. (Nasdaq: VTYX), announced today the closing of its upsized initial public offering of 10,893,554 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,420,898 additional shares, at an initial public offering price of $16.00 per share.

Angel Pharmaceuticals Co., Ltd. announced that its IND application for CPI-818, a small molecule ITK inhibitor, has been approved by the Center for Drug Evaluation to initiate clinical trials in patients with relapsed/refractory T-cell lymphomas in China.

Exact Sciences Corp. shared data from modeling analyses that demonstrate Cologuard, with its included patient navigation system, provides a greater reduction in incidence and mortality from colorectal cancer compared to annual fecal immunochemical test, when it included outreach, with or without a mailed annual FIT, using real world adherence rates in a simulated Medicaid population.

Vicore Pharma Holding AB, a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, announces that the results of the COVID-19 phase 2 trial of its angiotensin II type 2 receptor agonist C21 have been published in EClinicalMedicine, a peer reviewed clinical journal, published by The Lancet.